1Swanson SG, Drosman S, Helmond FA, et al. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postm- enopausal women : a multicenter, randomized, double-blind, placebo-con- trolled study. Menopause ,2006,13:917-925.
2Landgren MB, Bennink H J, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. Bjog, 2002,109 : 1109-1114.
3Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in ol- der postmenopansal women. New Engl J Med ,2008,359:697-708.
4Nijland EA, Weijmar-Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas, 2007,58 : 164-173.
5Nappi RE, Sances G, Sommaeal A, et al. Different effects of tibolone and low-dose EPT in the management of postmenopansal women with primary headaches. Menooause .2006.13 _. 818 -825.
6Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density : the Women' s Health Initiative randomized trial. JAMA ,2003,290 : 1729-1738.
7Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet,2003,361:296 -300.
8Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on car- diovascular events and breast cancer in postmenopausal women. N Engl J Med,2006,355:125-137.
9Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibo- lone in breast-cancer patients with vasomotor symptoms : a double-blind, randomised, non-inferiority trial. Lancet ,2009,10 : 135-146.
10Renoux C, DeU~niello S, Suissa S, et al. Hormone replacement therapy and the risk of venous thremboembolism: population-based study. J Thromb Haemost ,2010,8:979-986.
